214 results about "Osteoclast" patented technology

The invention provides a bacterial strain for improving bone health and application of the bacterial strain. The preservation number of bifidobacterium animalis subsp. Lactis BL-11 is CGMCC (China General Microbiological Culture Collection Center) No.20847. The strain can promote osteoblasts and inhibit osteoclasts in a cell experiment; by constructing a mouse model with abnormal bone growth, the BL-11 probiotics have an obvious improvement effect on bone development indexes of the model mouse, promote bone formation and inhibit bone resorption; furthermore, the BL-11 probiotics can improve the ostealgia score, life quality and bone mineral density of people with osteoporosis or bone mass reduction. The results indicate the application potential of the probiotics in improvement of abnormal bone growth and prevention and treatment of osteoporosis.

The invention relates to the technical field of biological medicines, and provides application of an ADRM1 inhibitor in preparation of a medicine for treating osteoporosis. Through the scheme of the invention, the ADRM1 affects bone metabolism, bone tissue morphological structure and osteoporosis progress, and can provide a new drug target for clinical prevention and treatment of osteoporosis. The ADRM1 inhibitor is applied to preparation of the osteoporosis medicine, and bone mass loss can be obviously reduced by down-regulating ADRM1 expression or inhibiting ADRM1 activity and inhibiting differentiation and functions of osteoclasts, so that the effect of treating osteoporosis is achieved.

Provided are compositions comprising a HKUOT-S2 protein, at least one peptide according to at least one of SEQ ID NO: 81-97, or a protein comprising an amino acid sequence according to at least one of SEQ ID NO: 81-97. Methods of osteogenesis are provided, including, for example, methods of enhancing bone repair, modulating polarization of macrophages with proinflammatory and anti-inflammatory activity and bone resorption of osteoclasts, and methods of treating inflammatory diseases, spinal cord injury, liver and kidney diseases, cardiovascular diseases, diabetes, post-menopausal syndrome, infertility, or hematopoietic diseases, or enhancing wound healing.

The invention provides a composition of a salvianolic acid extract and a tanshinone extract as well as a preparation method, application and a product of the composition, and belongs to the field of medicines. The preparation method of the composition of the salvianolic acid extract and the tanshinone extract comprises steps 1)-4). The composition with carbonic anhydrase inhibitory activity is obtained by extracting the salvianolic acid extract and the tanshinone extract from the radix salviae miltiorrhizae and mixing the salvianolic acid extract and the tanshinone extract, the composition can achieve synergistic interaction, and reference is provided for research and development and component compatibility of medicines mainly comprising the radix salviae miltiorrhizae. The composition provided by the invention can be used for reducing intraocular pressure, inducing diuresis, correcting metabolic acidosis, increasing vascular oxygen flux, improving pulmonary ventilatory capacity, expanding cerebral vessels, inducing tumor cell apoptosis and inhibiting osteoclast bone resorption; the traditional Chinese medicine composition can be used for treating or preventing diseases with intraocular hypertension as symptoms, cardiac edema or acute altitude sickness, cardiovascular and cerebrovascular diseases and bone metabolism diseases caused by osteoporosis.

A method for constructing a microfluidic bone organoid-on-chip can continuously observe the impacts of different external factors on a bone tissue structure based on the “ternary regulation theory” of bone angiogenesis-bone resorption-osteogenesis coupling. The method includes: (1) building a visual three-dimensional cell cultivation platform to continuously observe impacts of different external factors on a ternary regulation theory based on angiogenesis of osteoclast precursors, osteoblasts and osteoclasts, such that a user is allowed to directly observe interactions among various kinds of cells; (2) designing microfluidic channels in a chip to allow a reagent involved to present a concentration gradient distribution in the chip; and (3) adding three bioinks including osteoblasts, osteoclasts and vascular endothelial cells respectively, so as to reflect the three cell components individually, in pairs, and as a whole in the chip. An apparatus for constructing a microfluidic bone organoid-on-chip is further provided.

The invention discloses an artificial bone for promoting osteoporotic bone defect repair and a preparation method thereof, and belongs to the technical field of biomedical materials. The artificial bone disclosed by the invention is prepared by compounding the following components in percentage by weight: 89.65 to 89.85 weight percent of polylactic acid-glycolic acid copolymer, 9.85 to 10.15 weight percent of nano hydroxyapatite and 0.1 to 0.5 weight percent of zoledronic acid. In the artificial bone, the nano-hydroxyapatite and zoledronic acid are uniformly dispersed in the polylactic acid-glycolic acid copolymer, and the porous structure on the surface of the artificial bone is combined, so that osteoblasts can be attached to the surface of the artificial bone, and new bone tissues can grow in the artificial bone; phosphonate radicals of zoledronic acid can be chelated with nano-hydroxyapatite to generate stable chemical bonds, the stable chemical bonds are introduced into the polylactic acid-glycolic acid copolymer, effective loading of zoledronic acid can be achieved, and the effective loading of zoledronic acid can inhibit bone resorption increase caused by overactivation of osteoclasts and repair osteoporotic bone defects.

The invention discloses combined lactobacillus salivarius CCFM1327 capable of inhibiting foaming of macrophages and relieving periodontitis, and belongs to the technical field of microorganisms. According to the invention, the strain of combined lactobacillus salivarius CCFM1327 is obtained, and the combined lactobacillus salivarius has the effects of inhibiting foaming of macrophages and relieving periodontitis, which are specifically reflected in that the combined lactobacillus salivarius can inhibit foaming of RAW264.7 cells caused by ox-LDL; the growth of porphyromonas gingivalis can be effectively inhibited; the periodontal probing and diagnosing depth of the periodontitis rats can be obviously reduced; the number of pathogenic bacteria in the oral cavity of the periodontitis rat is reduced; the level of an inflammatory factor IL-17A in serum is reduced; alveolar bone loss of rats suffering from periodontitis is reduced; and the number of alveolar bone osteoclasts is reduced.

The invention relates to the field of application of medicines for treating rheumatoid arthritis, and discloses an application method of targeted MTHFD2 in preparation of medicines for treating bone destruction of rheumatoid arthritis, (1) the level of MTHFD2 in knee joints of rheumatoid arthritis patients and mice is increased; (2) the expression of MTHFD2 is up-regulated in the process of differentiating osteoclast precursor cells from mice and humans into osteoclasts; (3) the MTHFD2 inhibitor can significantly inhibit differentiation of osteoclasts from mice and humans; (4) MTHFD2 gene silencing can inhibit differentiation of mouse-derived osteoclasts, MTHFD2 gene overexpression can promote differentiation of osteoclasts, and reliability of MTHFD2 as a therapeutic target is verified; and (5) the MTHFD2 inhibitor can improve the bone destruction of arthritis mice and increase the bone tissue density, which prompts that the targeted MTHFD2 is useful for the treatment or prevention of rheumatoid arthritis and other diseases.

The invention provides a composite hydrogel for infectious bone defect repair and a preparation method thereof, and belongs to the technical field of bone defect repair, the composite hydrogel comprises a three-dimensional porous network structure hydrogel and a bioactive unit, and the bioactive unit is loaded in the three-dimensional porous network structure hydrogel; the hydrogel with the three-dimensional porous network structure is prepared from photo-crosslinked methacrylated silk fibroin and nano-hydroxyapatite; the bioactive unit comprises a strontium metal organic framework loaded with curcumin. According to the invention, the photo-crosslinked methacrylated silk fibroin provides excellent biocompatibility; as an ion / drug dual carrier, the strontium metal organic framework can continuously release strontium ions and bidirectionally regulate bone metabolism (promoting osteogenesis and inhibiting osteoclast), and the porous structure of the strontium metal organic framework can efficiently load a hydrophobic drug curcumin (Cur). Curcumin has strong antibacterial and anti-inflammatory functions; the nano-hydroxyapatite can obviously enhance the mechanical strength of the hydrogel.

The invention relates to the technical field of medicine, in particular to application of beta-hydroxybutyric acid in preparation of medicine for preventing and / or treating osteoporosis, the osteoporosis comprises postmenopausal osteoporosis and diabetic osteoporosis due to estrogen deficiency, the administration concentration of the beta-hydroxybutyric acid is 150mM, and the administration concentration of the beta-hydroxybutyric acid is 10mM. According to the application of the beta-hydroxybutyric acid in preparing the medicine for inhibiting osteoclast differentiation or osteoclast formation, the beta-hydroxybutyric acid inhibits osteoclast precursor cells from being differentiated into osteoclasts, and the administration concentration of the beta-hydroxybutyric acid is 10 mM; the invention proves that the beta-hydroxybutyric acid improves bone microstructures of OVX mice and db / db mice, inhibits osteoclast differentiation and reduces bone resorption, and provides a new target for prevention and treatment of osteoporosis.

The invention discloses magnesium-containing mesoporous active bioglass with drug sustained release, immunoregulation and bone metabolism regulation effects and application thereof. The drug-loaded MBGN is prepared by doping Mg ions and loading drugs, and the drug-loaded MBGN has good biocompatibility and can be decomposed in an acid environment to achieve controllable slow release of the drugs; on the other hand, released ions such as Si, Ca and Mg have a certain immunoregulation function, polarization of macrophages from M1 type to M2 type is promoted, inflammatory response is reduced, differentiation and maturation of osteoclasts are inhibited, and meanwhile, the released ions and drugs carried in mesopores play a synergistic effect, so that a good treatment effect is achieved. The drug-loaded MBGN provided by the invention has various biological properties, can overcome the defects of low drug loading rate, insufficient anti-inflammatory effect and the like when the existing mesoporous bioactive glass material is applied clinically, and has a good application prospect.

The invention discloses application of cimiprevir in preparation of a bacteriostatic agent and a medicine for preventing and treating periodontitis, and relates to the technical field of disease treatment by using cimiprevir. Studies find that cimiprevir can be combined with EF-Tu protein to inhibit adhesion of the EF-Tu protein to an interface, further inhibit adhesion of bacteria (especially oral streptococcus) to an oral interface and formation of a plaque biofilm, regulate proliferation and growth of the bacteria and play an effective bacteriostatic role, and cimiprevir can be used for preparing a bacteriostatic agent or a preparation for preventing and treating periodontitis; the composition can effectively reduce periodontal tissue damage, reduce alveolar bone absorption and reduce osteoclast infiltration, and is used for preparing a preparation for protecting periodontal tissue or alveolar bone.

The invention discloses combined lactobacillus salivarius CCFM1398 for regulating and controlling bone homeostasis and relieving bone resorption and a metagen of the combined lactobacillus salivarius CCFM1398, and belongs to the technical field of microorganisms. The combined lactobacillus salivarius CCFM1398 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that expression of protein level and gene level of MC3T3-E1 cell osteoprotegerin (OPG) is improved in vitro; the bone absorption amount of orthodontic bone absorption rat alveolar bone is reduced, the number of alveolar bone osteoclasts is reduced, and the level of rat serum OPG is improved; the secretion of inflammatory factors TNF-alpha, IL-6 and MPO of the orthodontic bone absorption rat is reduced; and the pathological condition of orthodontic bone absorption rat alveolar bone tissue is improved. Therefore, the combined lactobacillus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The present invention relates to a nanomaterial for preventing tumor bone metastasis, a preparation method therefor, and use thereof. The present invention has discovered a spatiotemporal coupling interaction between tumor cells and osteoclasts, and provides a tumor-bone initial metastasis behavior-targeting strategy which can accurately prevent tumor metastasis on the basis of the source, and can avoid drug resistance and biochemical drug resistance. On this basis, the present invention designs a physical killing nanomaterial targeting tumor-osteoclast conjugates, the nanomaterial being a bone targeting group-modified nanovesicle encapsulating a carbonate compound and a phosphate compound. The nanomaterial can be effectively concentrated in bone tissue; when tumor cells are activated, the acid secretion function of tumor-related osteoclasts in nearby tumor-osteoclast conjugates which are in contact with the tumor cells triggers the carbonate compound to generate carbon dioxide gas and promotes the release of the phosphate compound, which forms calcium phosphate crystals with calcium ions so as to kill nearby tumor cells, thus achieving a specific very-early tumor metastasis inhibition effect.

The invention discloses a combined lactobacillus salivarius CCFM1397 for improving osteoblast activity and relieving bone resorption and periodontal tissue damage and a metagen thereof, and belongs to the technical field of microorganisms. The lactobacillus salivarius combination CCFM1397 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that: the expression of MC3T3-E1 cell osteoprotegerin (OPG) protein and gene level is improved in vitro; the bone absorption amount of orthodontic bone absorption rat alveolar bone is reduced, the number of alveolar bone osteoclasts is reduced, and the level of rat serum OPG is improved; the secretion of inflammatory factors IL-1beta, IL-6 and TNF-alpha and myeloperoxidase MPO of the orthodontic bone absorption rats is reduced; and the pathological condition of orthodontic bone absorption rat alveolar bone tissue is improved. Therefore, the combined lactobacillus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention relates to application of an oroxylum indicum flavone extract in tumor-induced bone destruction, and relates to the field of biological medicines. The oroxylum indicum flavone extract comprises at least one of oroxylum indicum A and oroxylum indicum B, can inhibit tumor-induced osteoclast generation, can be used as a tumor-induced osteoclast differentiation inhibitor drug, and is used for treating tumor-induced bone destruction osteoclast activity abnormity diseases.

The invention provides a construction method and application of a transgenic animal model with osteoclast specific deletion, and belongs to the technical field of gene engineering. The invention provides a method for constructing an animal model of an osteoclast expression diphtheria toxin receptor, and particularly provides a method for constructing the animal model of the osteoclast expression diphtheria toxin receptor by using a Cre-loxP method. According to the method, the diphtheria toxin receptor is specifically expressed in the osteoclast, and the osteoclast can be specifically deleted by injecting the diphtheria toxin. The animal model of the osteoclast expression diphtheria toxin receptor prepared by the method can stably inherit after being established, is economical and reliable, can provide important theoretical and practical guidance for bone tumor treatment, also provides powerful animal model support for research of bone tumor growth correlation, and has a wide application prospect. Technical conditions are provided for screening, developing, preventing or treating medicines for bone tumors.

The application discloses a flavonoid compound in eaglewood as well as a preparation method and application of the flavonoid compound, and relates to the technical field of medicines. The application extracts and separates a new compound from natural eaglewood, and the new compound is used in the preparation of anti-osteoporosis drugs. The compound is detected in vitro to obtain an induction effect of the compound on the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteoblasts, so as to affect the formation of osteoclasts. Meanwhile, the compound can promote the bone development of zebra fish through RT-qPCR detection, which indicates that the compound has anti-osteoporosis activity. The separation method of the compound is simple and easy to operate.

The invention belongs to the field of medicine, and discloses application of POCM-NP-coated A939572 in preparation of a medicine for treating osteoporosis, the POCM-NP-coated A939572 comprises osteoclast precursor cell membrane vesicles and NP-coated A939572 loaded on the osteoclast precursor cell membrane vesicles, and the NP-coated A939572 is PLGA (poly (lactic-co-glycolic acid)) nanoparticles entrapped with the NP-coated A939572. The POCM-NP-coated A939572 obtained by loading the nanoparticles loaded with the A939572 small molecule medicine into the osteoclast precursor cell membrane vesicles has the effect of relieving the osteoporosis, can inhibit osteoclast differentiation and can be used for preventing, treating and relieving the osteoporosis.

The invention discloses a tetrahydro-beta-carboline compound as well as a preparation method and application thereof. The tetrahydro-beta-carboline compound is shown as a formula P. The tetrahydro-beta-carboline compound has good RANKL inhibitory activity, the preparation method is simple, raw materials are easy to obtain, and the yield is high. The inhibition activity of the compound on generation of RANKL-induced osteoclasts is determined through a tartrate acid phosphatase (TRAP) staining experiment, it is determined through a surface plasmon resonance (SPR) that the compound has high combining capacity with RANKL protein, and the compound can be used for preparing drugs for preventing and / or treating diseases caused by abnormal osteoclast activity. # imgabs0 #

The invention discloses application of a compound with a benzo-aza structure in preparation of a medicine for inhibiting osteoclast formation, the structure of the compound is shown as a formula (1), and R substituent is one of H, OCH3, Br, F and i-Pr. Cell experiments prove that the compound with the benzo-aza structure has a remarkable inhibiting effect on RANKL-induced osteoclast differentiation and marker gene expression, can be used as a candidate medicine which is novel in structure and is used for inhibiting osteoclast formation, and is used for targeting osteoclast to treat osteoporosis related diseases.

The invention provides a plant lactobacillus IOB602 for regulating bone metabolism and application thereof, and relates to the technical field of microorganisms. The strain is classified and named as lactobacillus plantarum, and is preserved in the China General Microbiological Culture Collection Center on June 29, 2018, the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC No.16021, and the preservation number is CGMCC No.16021. The invention further discloses a preparation method of the lactobacillus plantarum. The bacterium reduces the content of malondialdehyde as a lipid peroxidation product and increases the content of antioxidant enzyme, and has important significance in relieving damage of ROS to bone cells, regulating balance of osteoblasts and osteoclasts, improving bone metabolism and preventing and treating diabetic osteoporosis.

The invention relates to the technical field of gene therapy and drug development, and provides application of a UCH37 inhibitor in preparation of a drug for treating osteoporosis. The expression level of UCH37 in blood of osteoporosis patients is obviously higher than that of UCH37 in blood of healthy people, and the UCH37 is in positive correlation with osteoclast active markers such as NFATC1 and MMP9. The UCH37 inhibitor is applied to preparation of the medicine for treating osteoporosis and directly targets UCH37, the curative effect does not depend on the expression change of ADRM1, no matter the ADRM1 of osteoporosis patients is in a low or high expression state, an osteoclast activation pathway can be stably blocked, the consistency of treatment effects of different individuals is ensured, the range of applicable people of the medicine is expanded, and the application prospect is broad. The compound has the characteristics of clear action mechanism and wide application range, and provides important theoretical basis and conversion prospect for developing novel and efficient medicines for treating osteoporosis.

The invention discloses an application of polygonatum kingianum exosome in preparation of medicines for preventing and treating osteoporosis, the polygonatum kingianum exosome has good biocompatibility, can significantly inhibit osteoclast differentiation, promote osteocyte differentiation, effectively target bone tissues and significantly improve osteoporosis conditions, and has potential in preparation of medicines for preventing and treating osteoporosis. The polygonatum kingianum exosome is rich in source, has natural components with potential activity, is low in cost and is suitable for large-scale batch production.

The present invention relates to a composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.

The present invention relates to a ginseng peptide and a preparation method and application thereof, belonging to the field of biotechnology. The present invention provides a ginseng peptide, wherein the ginseng peptide comprises a characteristic peptide having an amino acid sequence of at least one of LY, MM, LR, AP, LAR, RLDFR, SALAFR, LLLLGH and LLLLLHG. The present invention obtains ginseng peptides by treating fermented ginseng residue, and identifies the characteristic peptides containing the amino acid sequences of LY, MM, LR, AP, LAR, RLDFR, SALAFR, LLLLGH and LLLLLHG in the ginseng peptides by HPLC-MS / MS. The present invention confirms through experiments that ginseng peptides and fermented ginseng hydrolysates containing ginseng peptides have excellent efficacy in inhibiting the differentiation of bone marrow mononuclear cells into osteoclasts, can improve hormone-induced osteoporosis, and can be applied to products for improving osteoporosis and its related symptoms.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for treating osteoporosis and a preparation and application thereof. The pharmaceutical composition is prepared from icariin, echinacoside, leonurus glycoside and cordycepin as raw materials according to a certain weight percentage. The traditional Chinese medicine composition can be prepared into various clinical common oral preparations. Pharmacological experiments show that the pharmaceutical composition can significantly inhibit the formation of osteoclasts in vitro. In addition, the pharmaceutical composition disclosed by the invention can be used for remarkably improving the bone mineral density value and the number of bone trabecula of ovariectomized mice. Experimental results also show that after icariin, echinacoside, leonurus glycoside and cordycepin are combined for use, a remarkable synergistic interaction effect is achieved. The pharmaceutical composition disclosed by the invention has a prospect of being developed into a medicine for treating osteoporosis, and has important social benefits and economic benefits.

The invention provides application of linariin-6-O-glucoside in preparation of a product for preventing and treating osteoporosis, and relates to the field of biological medicine. According to the invention, dyeing experiments of alkaline phosphatase, alizarin red and tartaric acid resistant acid phosphatase prove that the sesaminin-6-O-glucoside has affinity for FPPS receptors, has the capability of promoting bone marrow mesenchymal stem cells to form bone cells, is superior to that of bisphosphate, and can inhibit the generation of osteoclasts; microCT (micro computed tomography) detection results show that the sesaminin-6-O-glucoside has the effect of relieving the osteoporosis and can promote the formation of bone trabecula. According to the application disclosed by the invention, it is proved for the first time that the sesaminin-6-O-glucoside has the effect of resisting osteoclast formation, and meanwhile, the sesaminin-6-O-glucoside also has a better osteogenesis effect, so that a basis is provided for developing the sesaminin-6-O-glucoside as a potential medicine for treating osteoporosis.

The invention belongs to the technical field of biological medicines, and particularly provides application of Schwann cell exosomes in preparation of medicines for treating osteoporosis. An exosome derived from Schwann cells is prepared, and the inhibition effect of SC-EXO on osteoclasts is proved through TRAP staining, immunofluorescence, bone resorption, RT-qPCR and other experiments on the cell molecule level; meanwhile, the effect of SC-EXO on reduction of bone loss of ovarian extirpation mice is determined through in-vivo experiments. According to the invention, osteoclast formation and bone resorption capability can be inhibited, bone loss of OVX mice can be reduced in vivo, and the compound can be used for treating osteoporosis and other related diseases.

The present invention provides methods of inhibiting osteoclastogenesis or inhibiting osteoclast activity using fused imidazole derivative compounds and pharmaceutical compositions. These methods may be used to treat various bone destructive disorders.